Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK).
Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Léger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF. Ghielmini M, et al. Among authors: wernli m. Ann Oncol. 2005 Oct;16(10):1675-82. doi: 10.1093/annonc/mdi320. Epub 2005 Jul 19. Ann Oncol. 2005. PMID: 16030029 Free article. Clinical Trial.
Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK).
Betticher DC, Ratschiller D, Hsu Schmitz SF, von Rohr A, Hess U, Zulian G, Wernli M, Tichelli A, Tobler A, Fey MF, Cerny T. Betticher DC, et al. Among authors: wernli m. Ann Oncol. 1998 Jul;9(7):721-6. doi: 10.1023/a:1008273131598. Ann Oncol. 1998. PMID: 9739437 Free article. Clinical Trial.
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB. Betticher DC, et al. Among authors: wernli m. J Clin Oncol. 2003 May 1;21(9):1752-9. doi: 10.1200/JCO.2003.11.040. J Clin Oncol. 2003. PMID: 12721251 Clinical Trial.
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study.
von Rohr A, Schmitz SF, Tichelli A, Hess U, Piguet D, Wernli M, Frickhofen N, Konwalinka G, Zulian G, Ghielmini M, Rufener B, Racine C, Fey MF, Cerny T, Betticher D, Tobler A; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. von Rohr A, et al. Among authors: wernli m. Ann Oncol. 2002 Oct;13(10):1641-9. doi: 10.1093/annonc/mdf272. Ann Oncol. 2002. PMID: 12377655 Free article. Clinical Trial.
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study.
Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, Schmid RA, Pless M, Habicht J, Roth AD, Spiliopoulos A, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris HB; Swiss Group for Clinical Cancer Research (SAKK). Betticher DC, et al. Among authors: wernli m. Br J Cancer. 2006 Apr 24;94(8):1099-106. doi: 10.1038/sj.bjc.6603075. Br J Cancer. 2006. PMID: 16622435 Free PMC article. Clinical Trial.
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Roth AD, et al. Among authors: wernli m. J Clin Oncol. 2007 Aug 1;25(22):3217-23. doi: 10.1200/JCO.2006.08.0135. J Clin Oncol. 2007. PMID: 17664469 Clinical Trial.
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
Leyvraz S, Herrmann R, Guillou L, Honegger HP, Christinat A, Fey MF, Sessa C, Wernli M, Cerny T, Dietrich D, Pestalozzi B; Swiss Group for Clinical Cancer Research (SAKK). Leyvraz S, et al. Among authors: wernli m. Br J Cancer. 2006 Nov 20;95(10):1342-7. doi: 10.1038/sj.bjc.6603420. Epub 2006 Oct 10. Br J Cancer. 2006. PMID: 17031396 Free PMC article. Clinical Trial.
Intensive induction/consolidation therapy without maintenance in adult acute lymphoblastic leukaemia: a pilot assessment. Working Party on Leukaemia of the Swiss Group for Epidemiologic and Clinical Cancer Research (SAKK).
Wernli M, Tichelli A, von Fliedner V, Brun del Re G, Chapuis B, Fey MF, Fopp M, Gmür J, Grob JP, Jacky E, et al. Wernli M, et al. Br J Haematol. 1994 May;87(1):39-43. doi: 10.1111/j.1365-2141.1994.tb04867.x. Br J Haematol. 1994. PMID: 7947254 Clinical Trial.
109 results